DrugPatentWatch Database Preview
Patent: 8,748,626
Summary for Patent: 8,748,626
| Title: | Oxazole and thiazole compounds as KSP inhibitors |
| Abstract: | Disclosed are new substituted oxazole and thiazole compounds of Formula (I) and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the derivatives together with pharmaceutically acceptable carriers, and uses thereof: ##STR00001## |
| Inventor(s): | Barsanti; Paul A. (Pleasant Hill, CA), Ding; Yu (Union City, CA), Han; Wooseok (San Ramon, CA) |
| Assignee: | Novartis AG (Basel, CH) |
| Application Number: | 13/640,561 |
| Patent Claims: | see list of patent claims |
Details for Patent 8,748,626
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genentech | RITUXAN | rituximab | SOLUTION;INTRAVENOUS | 103705 | 001 | 1997-11-26 | Start Trial | Novartis AG (Basel, CH) | 2039-02-26 | RX | search | |
| Genentech | RITUXAN | rituximab | SOLUTION;INTRAVENOUS | 103705 | 002 | 1997-11-26 | Start Trial | Novartis AG (Basel, CH) | 2039-02-26 | RX | search | |
| Genentech | HERCEPTIN | trastuzumab | VIAL; INTRAVENOUS | 103792 | 001 | 1998-09-25 | Start Trial | Novartis AG (Basel, CH) | 2039-02-26 | RX | Orphan | search |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patent Family for US Patent 8,748,626
| Country | Patent Number | Publication Date |
|---|---|---|
| China | 103153970 | Jun 12, 2013 |
| European Patent Office | 2558452 | Feb 20, 2013 |
| Japan | 2013525290 | Jun 20, 2013 |
| >Country | >Patent Number | >Publication Date |
